Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at HC Wainwright

Esperion Therapeutics (NASDAQ:ESPR)‘s stock had its “buy” rating reiterated by HC Wainwright in a research report issued on Wednesday, Benzinga reports. They presently have a $16.00 target price on the biopharmaceutical company’s stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a report on Tuesday. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock traded down $0.13 during trading on Wednesday, hitting $2.24. The stock had a trading volume of 2,779,667 shares, compared to its average volume of 6,914,648. The business has a fifty day moving average of $2.32 and a two-hundred day moving average of $2.07. Esperion Therapeutics has a fifty-two week low of $0.70 and a fifty-two week high of $3.40. The firm has a market cap of $424.26 million, a P/E ratio of -1.06 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03. The business had revenue of $32.25 million for the quarter, compared to the consensus estimate of $26.84 million. During the same quarter last year, the business posted ($0.76) EPS. As a group, research analysts forecast that Esperion Therapeutics will post -0.68 earnings per share for the current year.

Institutional Investors Weigh In On Esperion Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Armistice Capital LLC bought a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $9,568,000. GSA Capital Partners LLP lifted its holdings in Esperion Therapeutics by 159.1% during the 3rd quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock valued at $1,094,000 after purchasing an additional 685,733 shares during the last quarter. Monaco Asset Management SAM increased its holdings in shares of Esperion Therapeutics by 68.5% during the third quarter. Monaco Asset Management SAM now owns 1,171,779 shares of the biopharmaceutical company’s stock worth $1,148,000 after buying an additional 476,477 shares in the last quarter. Wasatch Advisors LP boosted its holdings in shares of Esperion Therapeutics by 2.7% in the 1st quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock worth $24,467,000 after acquiring an additional 238,544 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its position in Esperion Therapeutics by 120.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock worth $405,000 after acquiring an additional 225,767 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.